Stockreport

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Acrivon Therapeutics, Inc.  (ACRV) 
PDF Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effec [Read more]